The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity

[1]  Division of Cancer Prevention , 2020, Definitions.

[2]  A. Kreger.  National Death Index , 1979, Definitions.

[3]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[4]  J. Ferreira,et al.  Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis , 2019, PloS one.

[5]  E. Petridou,et al.  Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review. , 2019, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[6]  M. Espié,et al.  Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab. , 2018, Breast.

[7]  L. Howie,et al.  A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review , 2018, JAMA oncology.

[8]  M. Bittencourt,et al.  Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. , 2018, Journal of the American College of Cardiology.

[9]  R. Touyz,et al.  Cardiotoxicity with vascular endothelial growth factor inhibitor therapy , 2018, npj Precision Oncology.

[10]  G. Cho,et al.  Global Longitudinal Strain to Predict Mortality in Patients With Acute Heart Failure. , 2018, Journal of the American College of Cardiology.

[11]  A. Asnani,et al.  Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management , 2018, Current Oncology Reports.

[12]  S. Ramsey,et al.  Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Gay,et al.  Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy , 2018, High Blood Pressure & Cardiovascular Prevention.

[14]  L. Jones,et al.  Exercise Therapy and Cardiovascular Toxicity in Cancer , 2018, Circulation.

[15]  E. Yow,et al.  Echocardiography Core Laboratory Reproducibility of Cardiac Safety Assessments in Cardio‐Oncology , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[16]  S. Mohile,et al.  Yoga for the Management of Cancer Treatment-Related Toxicities , 2018, Current Oncology Reports.

[17]  Adrienne Morgan,et al.  Review of systematic reviews of non-pharmacological interventions to improve quality of life in cancer survivors , 2017, BMJ Open.

[18]  A. DeMichele,et al.  Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. , 2017, Journal of the American College of Cardiology.

[19]  R. Kitsis,et al.  Grounding Cardio-Oncology in Basic and Clinical Science. , 2017, Circulation.

[20]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[21]  B. French,et al.  Detailed Echocardiographic Phenotyping in Breast Cancer PatientsClinical Perspective , 2017 .

[22]  D. Zardavas,et al.  Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Douglas,et al.  Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. French,et al.  Detailed Echocardiographic Phenotyping in Breast Cancer Patients Associations With Ejection Fraction Decline , Recovery , and Heart Failure Symptoms Over 3 Years of Follow-Up , 2017 .

[25]  P. Austin,et al.  A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer , 2017, JAMA cardiology.

[26]  Katherine E Henson,et al.  Cardiac Mortality Among 200 000 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age , 2016, Circulation.

[27]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[28]  C. Hudis,et al.  Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Lipshultz,et al.  Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[31]  L. Jones,et al.  Breast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures , 2016, Cardio-Oncology.

[32]  P. Nathan,et al.  Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. , 2016, The New England journal of medicine.

[33]  Michel G Khouri,et al.  Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. , 2015, Future cardiology.

[34]  P. Nathan,et al.  Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. , 2015, The Lancet. Oncology.

[35]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[36]  C. Cleeland,et al.  Predictors of significant worsening of patient‐reported fatigue over a 1‐month timeframe in ambulatory patients with common solid tumors , 2014, Cancer.

[37]  P. Hinds,et al.  Recommendations for high-priority research on cancer-related fatigue in children and adults. , 2013, Journal of the National Cancer Institute.

[38]  C. Heckler,et al.  Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. Fitzgerald,et al.  Response‐dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group , 2012, Pediatric blood & cancer.

[40]  R. Witteles,et al.  Underestimating cardiac toxicity in cancer trials: lessons learned? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Lipshultz,et al.  Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). , 2011, Blood.

[42]  T. Byers,et al.  Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study , 2011, Breast Cancer Research.

[43]  S. Lipsitz,et al.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. , 2010, The Lancet. Oncology.

[44]  M. Maitland,et al.  Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.

[45]  C. S. Turner,et al.  A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. , 2009, Blood.

[46]  S. Martino,et al.  Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  H. Dickinson,et al.  Cardioprotective interventions for cancer patients receiving anthracyclines. , 2008, The Cochrane database of systematic reviews.

[48]  D. Neuberg,et al.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. , 2007, Blood.

[49]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[51]  V. Ferrans,et al.  Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. , 1998, Current medicinal chemistry.

[52]  Rascon.  [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.